TY - JOUR
T1 - Anticancer effects of doxorubicin-conjugated magnetite MXene/Callicarpa extract on MCF-7 breast cancer cell line
AU - Jabbarzadeh, Mehdi
AU - Zaboli, Pardis
AU - Chekin, Fereshteh
AU - Saleh, Na'il
N1 - Publisher Copyright:
© 2025 Elsevier B.V.
PY - 2025/12/1
Y1 - 2025/12/1
N2 - Cancer is the most dangerous disease and second leading cause of death worldwide. Doxorubicin (DOX) is the most effective chemotherapeutic agent used for treating cancers. DOX possesses the side effects and strong cytotoxicity. Thus, it is urgent to develop the bio-carriers for loading this drug. In this work, we reported a novel platform based on MXene functionalized with Callicarpa extract and iron oxide nanoparticles (EX-Fe3O4-MX) for loading and release of DOX at different times and pHs and revealing the cytotoxicity of DOX@EX-Fe3O4-MX on breast cancer cell line (MCF-7) by MTT assay. The Raman, UV–Vis, XRD and FT-IR spectroscopy and FE-SEM images revealed DOX onto EX-Fe3O4-MX hybrid. FE-SEM images showed Fe3O4 nanoparticles with main particle size of 34.7 ± 2.6 nm on MXene layers. The 100 ppm of EX-Fe3O4-MX and DOX@EX-Fe3O4-MX showed 0.91 ppm and 0.84 ppm phenols with DPPH radical scavenging of 86.84 % and 75.93 %, respectively. The DOX-efficient loading, 88 % (at pH 7.0 for 4 h), was seen on EX-Fe3O4-MX in comparison to MX and Fe3O4-MX due to the presence of extract phenolic groups. The behavior of DOX@EX-Fe3O4-MX hybrid provided a biphasic release pattern consisting of an initial burst release, followed by a sustained drug release. Upon the normal physiological pH 7.0, the DOX-release content was 24.6 % from the DOX@EX-Fe3O4-MX at 12 h, while 72.1 % of DOX was released at pH 4.0. The 30.5 % and 73.6 % contents of DOX could be released after 25 h at pH 7.0 and 4.0, respectively. Cytotoxicity tests assessed significant viability loss, 41 % and 22 % after 24 and 48 h exposure, respectively for 4 μg/mL of DOX@EX-Fe3O4-MX. The viability loss of DOX@EX-Fe3O4-MX was comparable to free DOX with IC50 of ∼1 μg/mL after 48 h. All these findings imply that EX-Fe3O4-MX carrier offers significant benefits for biomedical applications and the design DOX@EX-Fe3O4-MX based-hybrid exhibits strong anticancer effect because of its remarkable properties, large surface area, and synergistic effects.
AB - Cancer is the most dangerous disease and second leading cause of death worldwide. Doxorubicin (DOX) is the most effective chemotherapeutic agent used for treating cancers. DOX possesses the side effects and strong cytotoxicity. Thus, it is urgent to develop the bio-carriers for loading this drug. In this work, we reported a novel platform based on MXene functionalized with Callicarpa extract and iron oxide nanoparticles (EX-Fe3O4-MX) for loading and release of DOX at different times and pHs and revealing the cytotoxicity of DOX@EX-Fe3O4-MX on breast cancer cell line (MCF-7) by MTT assay. The Raman, UV–Vis, XRD and FT-IR spectroscopy and FE-SEM images revealed DOX onto EX-Fe3O4-MX hybrid. FE-SEM images showed Fe3O4 nanoparticles with main particle size of 34.7 ± 2.6 nm on MXene layers. The 100 ppm of EX-Fe3O4-MX and DOX@EX-Fe3O4-MX showed 0.91 ppm and 0.84 ppm phenols with DPPH radical scavenging of 86.84 % and 75.93 %, respectively. The DOX-efficient loading, 88 % (at pH 7.0 for 4 h), was seen on EX-Fe3O4-MX in comparison to MX and Fe3O4-MX due to the presence of extract phenolic groups. The behavior of DOX@EX-Fe3O4-MX hybrid provided a biphasic release pattern consisting of an initial burst release, followed by a sustained drug release. Upon the normal physiological pH 7.0, the DOX-release content was 24.6 % from the DOX@EX-Fe3O4-MX at 12 h, while 72.1 % of DOX was released at pH 4.0. The 30.5 % and 73.6 % contents of DOX could be released after 25 h at pH 7.0 and 4.0, respectively. Cytotoxicity tests assessed significant viability loss, 41 % and 22 % after 24 and 48 h exposure, respectively for 4 μg/mL of DOX@EX-Fe3O4-MX. The viability loss of DOX@EX-Fe3O4-MX was comparable to free DOX with IC50 of ∼1 μg/mL after 48 h. All these findings imply that EX-Fe3O4-MX carrier offers significant benefits for biomedical applications and the design DOX@EX-Fe3O4-MX based-hybrid exhibits strong anticancer effect because of its remarkable properties, large surface area, and synergistic effects.
KW - Breast cancer
KW - Callicarpa extract
KW - Doxorubicin
KW - Iron oxide nanoparticles
KW - MXene
UR - http://www.scopus.com/inward/record.url?scp=105005842026&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=105005842026&partnerID=8YFLogxK
U2 - 10.1016/j.talanta.2025.128380
DO - 10.1016/j.talanta.2025.128380
M3 - Article
AN - SCOPUS:105005842026
SN - 0039-9140
VL - 295
JO - Talanta
JF - Talanta
M1 - 128380
ER -